Cardio Diagnostics Holdings, Inc. Expected to Earn Q2 2023 Earnings of ($0.21) Per Share (NASDAQ:CDIO)

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO – Get Rating) – Equities researchers at Northland Capmk issued their Q2 2023 EPS estimates for shares of Cardio Diagnostics in a note issued to investors on Monday, May 22nd. Northland Capmk analyst C. Byrnes expects that the company will post earnings of ($0.21) per share for the quarter. The consensus estimate for Cardio Diagnostics’ current full-year earnings is ($0.75) per share. Northland Capmk also issued estimates for Cardio Diagnostics’ Q3 2023 earnings at ($0.21) EPS, Q4 2023 earnings at ($0.21) EPS, FY2023 earnings at ($0.75) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.55) EPS.

Separately, Northland Securities began coverage on shares of Cardio Diagnostics in a research note on Monday. They set an “outperform” rating on the stock.

Cardio Diagnostics Stock Up 19.7 %

Cardio Diagnostics stock opened at $1.58 on Wednesday. Cardio Diagnostics has a 12-month low of $0.80 and a 12-month high of $10.25. The firm’s fifty day moving average price is $2.67 and its 200 day moving average price is $2.22.

Institutional Investors Weigh In On Cardio Diagnostics

Several hedge funds and other institutional investors have recently modified their holdings of CDIO. Susquehanna International Group LLP bought a new stake in shares of Cardio Diagnostics in the 4th quarter worth about $26,000. Bank of America Corp DE bought a new stake in shares of Cardio Diagnostics in the 1st quarter worth about $59,000. Geode Capital Management LLC bought a new stake in shares of Cardio Diagnostics in the 1st quarter worth about $290,000. Finally, State Street Corp bought a new stake in shares of Cardio Diagnostics in the 1st quarter worth about $163,000. Institutional investors own 77.29% of the company’s stock.

About Cardio Diagnostics

(Get Rating)

Cardio Diagnostics Holdings, Inc, a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.